Rosebengal Assisted Antimicrobial Photodynamic Therapy as an Adjunct To Mechanical Debridement In Non Surgical Management Of Periimplantitis- A Randomised Control Trial. - Nil

Start Date25 Apr 2024

Sponsor / Collaborator-

IRCT20100919004775N14 / RecruitingNot ApplicableIIT

The effect of aromatherapy with rose on anxiety and pain of patients before and after Endoscopic lithotripsy procedure

Start Date23 Oct 2022

Sponsor / Collaborator

Shiraz University of Medical Sciences

NCT05110001 / Active, not recruitingPhase 3IIT

Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction

Rose Bengal Electromagnetic Activation with Green light for Infection Reduction (REAGIR ) is an international, randomized, doubled masked, clinical trial. The purpose of this study is to determine differences in 6-month visual acuity between medical antimicrobial treatments alone versus antimicrobial treatment plus cross-linking with rose Bengal (RB-PDT).
Patients presenting to one of the Aravind Eye Hospitals in India or to the Federal University of São Paulo ophthalmology clinic in Brazil with either smear or culture positive fungal or acanthamoeba keratitis or smear and culture negative corneal ulcers and moderate to severe vision loss, defined as Snellen visual acuity of 20/40 or worse, will be eligible for inclusion. Those who agree to participate will be randomized to one of two treatment groups:
Group 4, Sham RB-PDT: topical chlorhexidine gluconate 0.02% (acanthamoeba), moxifloxacin 0.5% (smear/culture negative) or natamycin 5% (fungal keratitis) plus sham RB-PDT
Group 5, RB-PDT: topical chlorhexidine gluconate 0.02% (acanthamoeba), moxifloxacin 0.5% (smear/culture negative) or natamycin 5% (fungal keratitis) plus RB-PDT.

Start Date03 Aug 2022

Sponsor / Collaborator

The University of California, San Francisco

[+4]

100 Clinical Results associated with Rose Bengal disodium

100 Translational Medicine associated with Rose Bengal disodium

100 Patents (Medical) associated with Rose Bengal disodium

1,214

Literatures (Medical) associated with Rose Bengal disodium

01 Dec 2024·Cellular and Molecular Life Sciences

Molecular engineering of a spheroid-penetrating phage nanovector for photodynamic treatment of colon cancer cells

Article

Author: Kaltenbrunner, Alena ; Pellicioni, Valentina ; Nigro, Michela ; Danielli, Alberto ; Di Giosia, Matteo ; Pappagallo, Lucia ; Turrini, Eleonora ; Costantini, Paolo Emidio ; Catanzaro, Elena ; Cantelli, Andrea ; Petrosino, Annapaola ; Ulfo, Luca ; Calvaresi, Matteo ; Saporetti, Roberto ; Fimognari, Carmela

AbstractPhotodynamic therapy (PDT) represents an emerging strategy to treat various malignancies, including colorectal cancer (CC), the third most common cancer type. This work presents an engineered M13 phage retargeted towards CC cells through pentavalent display of a disulfide-constrained peptide nonamer. The M13CC nanovector was conjugated with the photosensitizer Rose Bengal (RB), and the photodynamic anticancer effects of the resulting M13CC-RB bioconjugate were investigated on CC cells. We show that upon irradiation M13CC-RB is able to impair CC cell viability, and that this effect depends on i) photosensitizer concentration and ii) targeting efficiency towards CC cell lines, proving the specificity of the vector compared to unmodified M13 phage. We also demonstrate that M13CC-RB enhances generation and intracellular accumulation of reactive oxygen species (ROS) triggering CC cell death. To further investigate the anticancer potential of M13CC-RB, we performed PDT experiments on 3D CC spheroids, proving, for the first time, the ability of engineered M13 phage conjugates to deeply penetrate multicellular spheroids. Moreover, significant photodynamic effects, including spheroid disruption and cytotoxicity, were readily triggered at picomolar concentrations of the phage vector. Taken together, our results promote engineered M13 phages as promising nanovector platform for targeted photosensitization, paving the way to novel adjuvant approaches to fight CC malignancies.

01 Oct 2024·Colloids and Surfaces B: Biointerfaces

pH-Induced conversion of bolaamphiphilic vesicles to reduction-responsive nanogels for enhanced Nile Red and Rose Bengal delivery

Article

Author: Galindo, Francisco ; Bedrina, Begoña ; Angulo-Pachón, César A ; Miravet, Juan F ; Bernal-Martínez, Ana M ; Hamley, Ian W ; Castelletto, Valeria

This study details the preparation and investigation of molecular nanogels formed by the self-assembly of bolaamphiphilic dipeptide derivatives containing a reduction-sensitive disulfide unit. The described bolaamphiphiles, featuring amino acid terminal groups, generate cationic vesicles at pH 4, which evolve into gel-like nanoparticles at pH 7. The critical aggregation concentration has been determined, and the nanogels' size and morphology have been characterized through Dynamic Light Scattering (DLS) and Transmission Electron Microscopy (TEM). Circular Dichroism (CD) spectroscopy reveals substantial molecular reconfigurations accompanying the pH shift. These nanogels enhance the in vitro cellular uptake of the lipophilic dye Nile Red and the ionic photosensitizer Rose Bengal into Human colon adenocarcinoma (HT-29) cells, eliminating the need for organic co-solvents in the former case. Fluorescence measurements with Nile Red as a probe indicate the reduction-sensitive disassembly of the nanogels. In photodynamic therapy (PDT) applications, Rose Bengal-loaded nanogels demonstrate notable improvements, with flow cytometry analysis evidencing increased apoptotic activity in the study with HT-29 cells.

01 Sep 2024·Current Eye Research

Comparison of Corneal Biomechanical Efficacy Between Rose Bengal-Green Light and Riboflavin-UVA Crosslinking

Article

Author: Saritas, Ozge ; Yesilirmak, Nilufer

PURPOSETo investigate corneal biomechanical changes after corneal cross-linking (CXL) treatments with rose bengal-green light (RB-CXL) and riboflavin-UVA (RF-CXL).METHODSA total of 60 freshly enucleated lamb eyes were obtained for this experimental study. Fifteen eyes were treated with RB-CXL using 0.1% RB solution (Group 1), 15 eyes were treated with RB-CXL using 0.2% RB solution (Group 2), 15 eyes were treated with RF-CXL using 0.1% RF solution (Group 3), and 15 eyes were used as controls (Group 4). The same treatment protocol (10-minute irradiation using a total of 5.4 J/cm² energy) was applied to all treatment groups. To evaluate corneal biomechanical changes, the stress-strain test was used for both the treated and control corneas. The elastic modulus was calculated using the tension strain curves obtained during the test.RESULTSThe average elastic modulus values were calculated to be 18.9, 23.5, 22.3, and 14.1 MPa in Groups 1, 2, 3, and 4, respectively. Statistically significant differences were found between the groups (p < 0.001 for Group 1 vs. 2; p < 0.001 for Group 1 vs. 3; p < 0.001 for Group 1 vs. 4; p = 0.002 for Group 2 vs. 3; p < 0.001 for Group 2 vs. 4; and p < 0.001 for Group 3 vs. 4).CONCLUSIONSIn this study, the efficacy of RB-CXL treatment applied using different concentrations of RB solutions at a total energy of 5.4 J/cm² was investigated, and 0.2% RB solution was found to have at least as much and even more effective than the RF-CXL (0.1% RF) on the corneal elasticity module. These results are encouraging for the treatment of ectatic corneas particularly below 400 μm. It is considered that the findings obtained from this study will guide future experimental and clinical studies.

News (Medical) associated with Rose Bengal disodium

21 May 2024

·www.biospace.com

Provectus Biopharmaceuticals Announces Poster Presentation of Rose Bengal Sodium for Treatment of Full-Thickness Cutaneous Wounds at SID 2024 Annual Meeting

Accelerates wound closure and improves wound healing KNOXVILLE, TN, May 21, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that non-clinical data on Provectus’s proprietary, pharmaceutical-grade, rose bengal sodium (“RBS”) active pharmaceutical ingredient for the topical treatment of full-thickness cutaneous wounds were presented at the annual meeting of the Society for Investigative Dermatology (“SID”), held May 15-18, 2024 in Dallas, Texas. This work is part of research being conducted by Amina El Ayadi, PhD, Assistant Professor, Surgical Sciences Division of the Burn, Trauma, and Critical Care Research Laboratory in the Department of Surgery at the University of Texas Medical Branch at Galveston (“UTMB”). A copy of UTMB’s poster presentation is available here: . The UTMB team and Dr. El Ayadi concluded that: The application of multidose 0.01% RBS every other day under ambient light (“RBS treatment”) to full-thickness wounds showed: No toxicity or mortality, No loss in body weight, No organ abnormalities, and No observed adverse effect level at the highest tested dose, Transepidermal water loss was significantly reduced by 14 days, suggesting improvement in skin barrier function, Erythema was increased at seven days, suggesting increased blood flow and granulation tissue formation required for wound healing, Vascularity was increased between three and seven days, supporting pro-angiogenic activity needed for wound closure, RBS treatment: Accelerated wound closure (significant difference at three days), Increased collagen density at seven and 14 days, supporting increased wound remodeling and tissue regeneration, and Reduced angiogenesis after wound closure (day 14), which is beneficial in preventing fibrosis. About University of Texas Medical Branch at Galveston Starting from the Texas City Disaster of 1947, the deadliest industrial accident in U.S. history and one of history’s largest non-nuclear explosions, UTMB clinicians and researchers in the Department of Surgery have developed treatments that improve the survival chances of patients with massive burns, reduce scar formation, and accelerate patient recovery. Many novel treatments discovered by UTMB researchers have been adopted by specialist burn centers around the world. The Department of Surgery’s Burn, Trauma, and Critical Care Research Laboratory is equipped with an array of cutting-edge equipment and technologies that support its research activities, including a dedicated cell culture suite, confocal microscope, flow cytometer, Comprehensive Lab Animal Monitoring System, and bioprinter for 3D cell culture. About Provectus Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of synthetic small molecule immuno-catalysts called halogenated xanthenes. Provectus’s lead HX molecule is named rose bengal sodium. Provectus’s medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; proof-of-concept in vivo development programs in oncology, hematology, full-thickness cutaneous wound healing, and canine cancers; and in vitro discovery programs in infectious diseases, tissue regeneration and repair, and proprietary targets. Information about the Company’s clinical trials can be found at the National Institutes of Health (NIH) registry, ClinicalTrials.gov. For additional information about Provectus, please visit the Company’s website at . FORWARD-LOOKING STATEMENTS: The information provided in this press release may include forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, relating to the business of Provectus and its affiliates, which are based on currently available information and current assumptions, expectations, and projections about future events and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Such statements are made in reliance on the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are often, but not always, identified by the use of words such as “aim,” “likely,” “outlook,” “seek,” “anticipate,” “budget,” “plan,” “continue,” “estimate,” “expect,” “forecast,” “may,” “will,” “would,” “project,” “projection,” “predict,” “potential,” “targeting,” “intend,” “can,” “could,” “might,” “should,” “believe,” and similar words suggesting future outcomes or statements regarding an outlook. The safety and efficacy of Provectus’s drug agents and/or their uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated or that such agents as products will achieve any revenue levels. Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof or as of the date specifically specified herein, and the Company undertakes no obligation to update or revise any forward-looking statements, whether because of new information, future events, or otherwise, except in accordance with applicable securities laws. The forward-looking statements are expressly qualified by this cautionary statement. Risks, uncertainties, and assumptions include those discussed in the Company’s filings with the Securities and Exchange Commission, including those described in Item 1A of the Company’s: Annual Report on Form 10-K for the period ended December 31, 2023, and Quarterly Report on Form 10-Q for the period ended March 31, 2024. ##### Contact: Provectus Biopharmaceuticals, Inc. Heather Raines, CPA Chief Financial Officer Phone: (866) 594-5999

Clinical Result

14 May 2024

·www.biospace.com

Provectus Biopharmaceuticals Announces Eight Presentations of Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2024 Annual Meeting

PDAT clinical outcomes for infectious keratitis from Brazil and Mexico KNOXVILLE, TN, May 14, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that clinical and non-clinical data on rose bengal photodynamic antimicrobial therapy (“RB PDAT”) were presented at the annual meeting of the Association for Research in Vision and Ophthalmology (“ARVO”), held May 5-9, 2024 in Seattle, Washington. The ARVO annual meeting brings together approximately 10,000 vision researchers, clinicians, and scientists from around the world for scientific sessions, poster presentations, and invited speaker sessions. Provectus entered into an exclusive worldwide license agreement with the University of Miami (the “University”) in April 2024 for its intellectual property related to RB PDAT for treating bacterial, fungal, and parasitic (acanthamoeba) eye infections. The Company and University plan to form a start-up biotechnology company (e.g., “Eyecare NewCo”), potentially in the third quarter of 2024, aimed at commercializing the University’s PDAT light source medical device in combination with a drug formulation of Provectus’s proprietary pharmaceutical-grade rose bengal active pharmaceutical ingredient (“RB API”). The Company would contribute the RB PDAT license to and have an exclusive RB API supply arrangement with Eyecare NewCo. RB PDAT emerged under the leadership of Jean-Marie Parel, IngETS-G, Ph.D., FARVO, Director of Bascom Palmer Eye Institute’s (“BPEI’s”) Ophthalmic Biophysics Center at the University of Miami Miller School of Medicine. Dr. Parel and the OBC team have spent more than ten years advancing RB PDAT technology against different types of infectious keratitis. ARVO 2024 RB PDAT presentations included: Evaluating the Safety of Rose Bengal Photodynamic Therapy, Huang et al., BPEI (Poster no. B0448, Session: Cornea), Rose Bengal Photodynamic Antimicrobial Therapy as an Adjuvant Treatment for Infectious Keratitis, Eskenazi-Betech et al., Instituto de Oftalmologia Fundacion Conde de Valenciana IAP (Mexico) (B0338, Cornea), Assessment of photosensitizer concentration with a Singlet Oxygen luminescence dosimeter for Photodynamic Antimicrobial Therapy, Carrera et al., BPEI (B0570, Cornea), Clinical outcome in patients with infectious keratitis treated with Rose Bengal Photodynamic Antimicrobial Therapy (RB-PDAT) at the Federal University of Sao Paulo (UNIFESP), Tabuse et al., Universidade Federal de São Paulo (Brazil) (B0575, Cornea), Enhanced Fungal Inhibition with High-Dose Rose Bengal Photodynamic Antimiocrobial Therapy, Merikansky et al., BPEI (B0580, Cornea), Inhibition of Fungal Isolates via Singlet Oxygen Generation from Erythrosin B and Rose Bengal Photodynamic Antimicrobial Therapy, Ahmed et al., BPEI (Paper no. 4917, Cornea), Arginine-Mediated Enhancement of Photodynamic Antimicrobial Therapy to Target the Oxygen-Independent Pathway, Gonzalez et al., BPEI (B0005, Immunology/Microbiology), and Preclinical/Poster: Exploring the Combination of Rose Bengal Photodynamic Antimicrobial Therapy and Existing Antifungals, Krishna et al., BPEI (B0010, Immunology/Microbiology). RB PDAT is the subject of two international Phase 3 randomized controlled trials for acanthamoeba and fungal (NCT05110001) and bacterial (NCT06271772) keratitis, and has been used to treat infectious keratitis patients in four countries to date: U.S.: BPEI (first clinical reporting: Naranjo et al. 2019), India: LV Prasad Eye Institute (Bagga et al. 2022) and Aravind Eye Care System (NCT05110001 data readout planned in Q4 2024), Brazil: Universidade Federal de São Paulo (ARVO 2024), and Mexico: Instituto de Oftalmología FAP (ARVO 2024). About Bascom Palmer Eye Institute Bascom Palmer Eye Institute serves as the Department of Ophthalmology for the University of Miami Miller School of Medicine. The mission of BPEI is to enhance the quality of life by improving sight, preventing blindness, and advancing ophthalmic knowledge through compassionate patient care and innovative research. For 2023-2024, U.S. News & World Report (“U.S. News”) ranked BPEI as the nation’s best in ophthalmology, marking the 22nd time and 20th consecutive year that BPEI has received the No. 1 ranking since U.S. News began surveying American physicians for its annual “Best Hospitals” rankings 34 years ago. About Provectus Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of synthetic small molecule immuno-catalysts called halogenated xanthenes. Provectus’s lead HX molecule is named rose bengal sodium. Provectus’s medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; proof-of-concept in vivo development programs in oncology, hematology, full-thickness cutaneous wound healing, and canine cancers; and in vitro discovery programs in infectious diseases, tissue regeneration and repair, and proprietary targets. Information about the Company’s clinical trials can be found at the National Institutes of Health (NIH) registry, ClinicalTrials.gov. For additional information about Provectus, please visit the Company’s website at . FORWARD-LOOKING STATEMENTS: The information provided in this press release may include forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, relating to the business of Provectus and its affiliates, which are based on currently available information and current assumptions, expectations, and projections about future events and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Such statements are made in reliance on the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are often, but not always, identified by the use of words such as “aim,” “likely,” “outlook,” “seek,” “anticipate,” “budget,” “plan,” “continue,” “estimate,” “expect,” “forecast,” “may,” “will,” “would,” “project,” “projection,” “predict,” “potential,” “targeting,” “intend,” “can,” “could,” “might,” “should,” “believe,” and similar words suggesting future outcomes or statements regarding an outlook. The safety and efficacy of Provectus’s drug agents and/or their uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated or that such agents as products will achieve any revenue levels. Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof or as of the date specifically specified herein, and the Company undertakes no obligation to update or revise any forward-looking statements, whether because of new information, future events, or otherwise, except in accordance with applicable securities laws. The forward-looking statements are expressly qualified by this cautionary statement. Risks, uncertainties, and assumptions include those discussed in the Company’s filings with the Securities and Exchange Commission, including those described in Item 1A of: The Company’s Annual Report on Form 10-K for the period ended December 31, 2023. ##### Contact: Provectus Biopharmaceuticals, Inc. Heather Raines, CPA Chief Financial Officer Phone: (866) 594-5999

License out/inPhase 3

02 May 2024

·www.globenewswire.com

Provectus Biopharmaceuticals Announces Notice of Allowance for U.S. Patent of Oral Administration of Rose Bengal Sodium in Hematology (Leukemia)

KNOXVILLE, TN, May 02, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that the United States Patent and Trademark Office has allowed patent application 17/232,393, titled “Halogenated Xanthene Composition and Method for Treating Hematologic Cancers” (formerly “Composition and Method for Oral Treatment of Leukemia”). The application covers the use of Provectus’s pharmaceutical grade rose bengal sodium (“RBS”) active pharmaceutical ingredient for the single agent or combination therapy treatment of pediatric and adult leukemias. Earlier this year, Provectus announced notices of allowance and award for U.S. patents of RBS in virology, pediatric solid tumor cancers, and vaccines. Innovate Calgary, the innovation company of the University of Calgary in Alberta, Canada, is a co-assignee and Aru Narendran, MD, PhD, Professor of Pediatrics, Oncology, Biochemistry and Molecular Biology and Physiology and Pharmacology at the University’s Cumming School of Medicine is a co-inventor on all four patent awards. Dominic Rodrigues, President and Vice Chairman of Provectus’s Board of Directors said, “As we remain focused on advancing intratumoral administered cancer immunotherapy PV-10 towards initial drug approval for metastatic pancreatic cancer, our evidence-based confidence in the potential and possibilities of oral administration of rose bengal sodium for the treatment of disease continues to grow.” About Provectus Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of synthetic small molecule immuno-catalysts called halogenated xanthenes. Provectus’s lead HX molecule is named rose bengal sodium. Provectus’s medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; proof-of-concept in vivo development programs in oncology, hematology, full-thickness cutaneous wound healing, and canine cancers; and in vitro discovery programs in infectious diseases, tissue regeneration and repair, and proprietary targets. Information about the Company’s clinical trials can be found at the National Institutes of Health (NIH) registry, ClinicalTrials.gov. For additional information about Provectus, please visit the Company’s website at www.provectusbio.com. FORWARD-LOOKING STATEMENTS: The information in this press release may include “forward-looking statements,” within the meaning of U.S. securities legislation, relating to the business of Provectus and its affiliates, which are based on the opinions and estimates of Company management and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek,” “anticipate,” “budget,” “plan,” “continue,” “estimate,” “expect,” “forecast,” “may,” “will,” “project,” “predict,” “potential,” “targeting,” “intend,” “could,” “might,” “should,” “believe,” and similar words suggesting future outcomes or statements regarding an outlook. The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated or that such agents as products will achieve any particular revenue levels. Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof or as of the date specifically specified herein, and Provectus undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except in accordance with applicable securities laws. The forward-looking statements are expressly qualified by this cautionary statement. Risks, uncertainties, and assumptions include those discussed in the Company’s filings with the Securities and Exchange Commission (SEC), including those described in Item 1A of: The Company’s Annual Report on Form 10-K for the period ended December 31, 2023. ##### Contact: Provectus Biopharmaceuticals, Inc.Heather Raines, CPAChief Financial OfficerPhone: (866) 594-5999

ImmunotherapyClinical Study

100 Deals associated with Rose Bengal disodium

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	S01JA02	DB11182

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Breast Cancer	Phase 3	-	Provectus LLC	-
Dermatitis, Atopic	Phase 3	-	Provectus LLC	-
Melanoma	Phase 3	-	Provectus LLC	-
Psoriasis	Phase 3	-	Provectus LLC	-
Locally Advanced Melanoma	Phase 1	DE	Provectus Biopharmaceuticals, Inc.	01 Apr 2015
Melanoma, Cutaneous Malignant	Phase 1	DE	Provectus Biopharmaceuticals, Inc.	01 Apr 2015
Melanoma, Cutaneous Malignant	Phase 1	MX	Provectus Biopharmaceuticals, Inc.	01 Apr 2015
Melanoma, Cutaneous Malignant	Phase 1	IT	Provectus Biopharmaceuticals, Inc.	01 Apr 2015
Melanoma, Cutaneous Malignant	Phase 1	US	Provectus Biopharmaceuticals, Inc.	01 Apr 2015
Melanoma, Cutaneous Malignant	Phase 1	FR	Provectus Biopharmaceuticals, Inc.	01 Apr 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02557321 (Biospace) Manual	Phase 1/2	Melanoma, Cutaneous Malignant	25	PV-10 + pembrolizumab (CB-naïve)	(tmarxsqtyb) = sydaxczomo gwwqzkitka (lprawrexdm ) View more	Positive	15 Nov 2023
				PV-10 + pembrolizumab (CB-naïve Stage III)	(tmarxsqtyb) = sgzczmuzof gwwqzkitka (lprawrexdm ) View more
NCT00986661 (GlobeNewswire) Manual	Phase 1	Uveal Melanoma	25	PV-10 or PV-10 +ipilimumab+nivolumab	(hdbfbxrpll) = hrczudqsnh wivrowxlkf (ocvaezdxji ) View more	Positive	13 Nov 2023
				PV-10 or PV-10 +ipilimumab+nivolumab (M1a)	(hdbfbxrpll) = kpauezyrvk wivrowxlkf (ocvaezdxji ) View more
SITC2023	Not Applicable	-	-	PV-10	jegntsyphh(zcbaakjymj) = rdngtwwwea fifmnwkycs (jeitzdyyba )	-	02 Nov 2023
				Placebo	jegntsyphh(zcbaakjymj) = lexlskslfh fifmnwkycs (jeitzdyyba )
NCT02288897 (CTgov)	Phase 3	Melanoma, Cutaneous Malignant \| Locally Advanced Melanoma	20	PV-10 (10% rose bengal disodium) (PV-10)	(kpcxrhtawn) = bzlxmhvgpk xxxwomlmhu (ofstahjobn, oorfntjztz - wjdioebkhp) View more	-	19 Jan 2022
				Dacarbazine, temozolomide or talimogene laherparepvec (Chemotherapy or Oncolytic Viral Therapy)	(kpcxrhtawn) = rbiojtxndf xxxwomlmhu (ofstahjobn, pnwudacdcd - uaxhedyjxj) View more
ESMO2021	Phase 1	Advanced Neuroendocrine Neoplasm	12	PV-10 IL single lesion per treatment cycle	(mzsmhvjmjg) = kvfqxjzvmt dwraugidly (yobsqzluib ) View more	-	16 Sep 2021
NCT02693067 (ASCO2021)	Phase 1	Neuroendocrine Tumors	12	PV-10	(aidjaxbaly) = snuoptgdom jvsytisyyv (rlbsyqsxoi ) View more	Positive	28 May 2021
NCT02693067 (ASCO2021)	Phase 1	Solid tumor	12	PV-10	hjmsmmkcue(nydcdomdux) = fnqvogarjb ezqoeughvw (ywkdhgqddv, 16.4)	-	28 May 2021
				PV-10 (Control)	hjmsmmkcue(nydcdomdux) = igubcbgsbu ezqoeughvw (ywkdhgqddv, 71.0)
NCT02557321 (PV-10-MM-1201, ESMO2020)	Phase 1/2	Melanoma, Cutaneous Malignant	21	PV-10 and pembrolizumab	(ijpdxngffd) = vhgsbcnfgm tvubprfvbg (kambhqxjjr ) View more	Positive	17 Sep 2020
NCT02557321 (PV-10-MM-1201, ESMO2020)	Phase 1/2	Melanoma, Cutaneous Malignant	13	PV-10 + Pembrolizumab	(qqjnmcljzp) = bsngcoefbl gtnsesmygl (ozzkuvpnnf ) View more	-	17 Sep 2020
NCT00986661 (ASCO2020)	Phase 1	Uveal Melanoma	15	PV-10	mtzchylzre(wiuoqubqbm) = AEs attributed to PV-10 were transient and included 3 cases of Grade 3/4 transaminitis that resolved within 72 hrs, injection site pain, photosensitivity, and pink discoloration of skin, urine or feces; AEs attributed to CB included nausea, decreased WBC, and fatigue. thuttamrjx (ikptvtsfhf )	-	25 May 2020

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis